June 2006 Research News

Tykerb Shows Benefit for HER2-positive, Herceptin-resistant Cancer
Early results show promise for women with advanced HER2-positive breast cancer that has stopped responding to Herceptin—the combination of Tykerb and Xeloda essentially delayed the cancer's growth nearly twice as long compared with Xeloda alone. Read more…

Five Years of Arimidex Can Cause Bone Loss in Women With Low Bone Density
Taking Arimidex for 5 years can lead to a 6% to 7% bone density loss in women who have lower bone density than normal when they begin treatment, but women who have normal bone density when they start taking Arimidex are unlikely to develop osteoporosis. Read more…

Switching to Aromasin After Tamoxifen May Reduce Risk of Recurrence
If you're a postmenopausal woman with early-stage, hormone-receptor-positive disease, and you're taking tamoxifen, you may be able to get greater benefit from switching to Aromasin for the rest of the 5 years (rather than staying on tamoxifen for the full 5 years). Read more…

Partial-Breast Irradiation Therapy With MammoSite Appears to Offer Similar Results as Whole-Breast Irradiation Therapy
Results over a very short period of follow-up show a low risk of recurrence after lumpectomy and partial-breast irradiation therapy. While the results are promising, they are only preliminary. Read more…